Pixium Vision convenes a Combined General Meeting of Shareholders on April 19, 2022
Pixium Vision convenes aCombined General Meeting of Shareholders on April 19, 2022
Paris, France,March14,2022 – 19:00 CET– Pixium Vision SA (Euronext Growth Paris - FR0011950641; Mnemo: ALPIX), a bioelectronics company that develops innovative bionic vision systems to enable patients who have lost their sight to live more independent lives, announces today that it will hold a combined general meeting of shareholders (CGM) at 10:00 CET on April 19, 2022 at Pixium Vision’s headquarter office. The meeting will take place in person.
Pixium Vision is calling this Combined General Meeting to seek approval from shareholders to obtain the necessary financial authorizations to give all the opportunities for the Company to secure appropriate funding for its clinical activities and upcoming commercial structure and for the pursuing of its strategic ambitions. The Company is evaluating several future financing options and investigating the best funding opportunities.
Information and documents relating to this General Meeting will be available on the Company's website as from the convening of the shareholders in accordance with applicable laws and regulations.
The Company will probably review the calendar of its Annual Shareholders Meeting already set on June 1, 2022.
About Pixium Vision
Pixium Vision is creating a world of bionic vision for those who have lost their sight, enabling them to regain visual perception and greater autonomy. Pixium Vision’s bionic vision systems are associated with a surgical intervention and a rehabilitation period. Prima System sub-retinal miniature photovoltaic wireless implant is in clinical testing for patients who have lost their sight due to outer retinal degeneration, initially for atrophic dry age-related macular degeneration (dry AMD). Pixium Vision collaborates closely with academic and research partners, including some of the most prestigious vision research institutions in the world, such as Stanford University in California, Institut de la Vision in Paris, Moorfields Eye Hospital in London, Institute of Ocular Microsurgery (IMO) in Barcelona, University hospital in Bonn, and UPMC in Pittsburgh, PA. The company is EN ISO 13485 certified and qualifies as “Entreprise Innovante” by Bpifrance.
For more information: http://www.pixium-vision.com/fr
Chief Financial Officer
+33 1 76 21 47 68
|Media Relations |
+33 6 27 74 74 49
Guillaume van Renterghem
+41 76 735 01 31
This press release may expressly or implicitly contain forward-looking statements relating to Pixium Vision and its activity. Such statements are related to known or unknown risks, uncertainties and other factors that could lead actual results, financial conditions, performance or achievements to differ materially from Vision Pixium results, financial conditions, performance or achievements expressed or implied by such forward looking statements.
Pixium Vision provides this press release as of the aforementioned date and does not commit to update forward looking statements contained herein, whether as a result of new information, future events or otherwise.
For a description of risks and uncertainties which could lead to discrepancies between actual results, financial condition, performance or achievements and those contained in the forward-looking statements, please refer to the "Risk Factors" (“Facteurs de risques”) section of the Company’s 2020 Financial Report, available on the website of the Company (www.pixium-vision.com).
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Sampo plc’s share buybacks 17/05/202218.5.2022 07:30:00 CEST | Press release
SAMPO PLC STOCK EXCHANGE RELEASE 18/05/2022 at 08:30 am Sampo plc’s share buybacks 17/05/2022 On 17/05/2022 Sampo plc (business code 0142213-3, LEI 743700UF3RL386WIDA22) has acquired its own A shares (ISIN code FI0009003305) as follows: Sampo plc’s share buybacksAggregated daily volume (in number of shares)Daily weighted average price of the purchased shares*Market (MIC Code)28,56046.33AQEU41,30446.31CEUX10,74946.33TQEX61,23946.32XHELTOTAL141,85246.32 *rounded to two decimals On 30 March 2022, Sampo announced a share buyback programme of up to a maximum of EUR 250 million in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052. The programme, which started on 31 March 2022, is based on the authorization granted by Sampo's Annual General Meeting on 19 May 2021. After the disclosed transactions, the company owns in total 4,961,994 Sampo A shares representing 0.92 per cent of the total number of shares in Sampo plc. Details
Bavarian Nordic skal producere de første frysetørrede doser af koppevaccinen efter udnyttelse af kontraktoption af den amerikanske regering18.5.2022 07:25:16 CEST | pressemeddelelse
Optioner på USD 119 mio. er udnyttet med henblik på produktion af frysetørret JYNNEOS® i 2023 og 2024Disse udgør de første optioner ud af en samlet kontrakt på USD 299 mio., der er beregnet til konvertering af eksisterende råvaccine, der allerede er indkøbt af BARDA, til ca. 13 mio. frysetørrede doser JYNNEOS KØBENHAVN, Danmark, 18. maj 2022 – Bavarian Nordic A/S (OMX: BAVA) meddelte i dag, at Biomedical Advanced Research and Development Authority (BARDA), en del af Office of the Assistant Secretary for Preparedness and Response ved U.S. Department of Health and Human Services, har udnyttet de første optioner i kontrakten på frysetørret JYNNEOS® koppevaccine, hvorved de første doser af denne formulering vil blive produceret og faktureret i 2023 og 2024. Optionerne har en værdi af USD 119 mio., og er de første optioner, der er udnyttet med henblik på at færdigproducere den råvaccine, der allerede er fremstillet og faktureret under tidligere kontrakter med BARDA, som frysetørret JYNNEOS
Bavarian Nordic to Manufacture First Freeze-dried Doses of Smallpox Vaccine upon Exercise of Contract Option by the U.S. Government18.5.2022 07:25:16 CEST | Press release
USD 119 million option exercised for the manufacturing of freeze-dried JYNNEOS® in 2023 and 2024This represents the first set of options with a total value of USD 299 million to convert the existing bulk vaccine, previously purchased by BARDA, to approximately 13 million freeze-dried JYNNEOS doses COPENHAGEN, Denmark, May 18, 2022 – Bavarian Nordic A/S (OMX: BAVA) announced today that the U.S. Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, has exercised the first options under the contract to supply a freeze-dried version of JYNNEOS® smallpox vaccine, thus allowing for the first doses of this version to be manufactured and invoiced in 2023 and 2024. The options have a value of USD 119 million and represent the first options exercised to convert bulk vaccine, which has already been manufactured and invoiced under previous contracts with BARDA,
Norrlandsfonden supports Copperstone Resources with funds18.5.2022 07:15:00 CEST | Press release
Kiruna May 18, 2022 Norrlandsfonden will invest further MSEK5.5 in a convertible debenture in Copperstone Resources AB (“Copperstone” or “the Company”). In accordance with the existing loan agreement in connection with fund raisings, Norrlandsfonden has the right, but not obligation, to invest in Copperstone. The credit facilities are agreed at Stibor 90 + 5 percent annually, with quarterly interest payments. Norrlandsfonden is entitled to convert parts of the, or the entire, amount until April 30, 2027. The conversion prices shall be 1.54 SEK/share, corresponding to a 40 percent premium from the volume weighted average of the recent directed equity issues at approximately 1.1 SEK per share. At full conversion of the debenture, Norrlandsfonden would receive 3,571,428 shares of Copperstone, corresponding to a dilution of 0.3%. “We are very pleased and proud that Norrlandsfonden once again has decided to support Copperstone. The increased working capital comes in very handy now that also
Norrlandsfonden investerar i Copperstone Resources18.5.2022 07:15:00 CEST | Pressemelding
Kiruna den 18 maj 2022 Norrlandsfonden har valt att investera ytterligare 5,5 MSEK i ett konvertibelt skuldebrev i Copperstone Resources AB (”Copperstone” eller ”Bolaget”). I enlighet med existerande låneavtal äger Norrlandsfonden rätt, men inte skyldighet, att stödja Copperstone i samband med kapitalanskaffningar. Lånet löper med Stibor 90 + 5 procents årlig ränta med kvartalsvisa räntebetalningar. Norrlandsfonden äger rätt att fram till den 30 april 2027 påkalla konvertering av hela eller delar av det nominella beloppet. Konverteringspriset kommer uppgå till 1,54 SEK/aktie, motsvarande 40 procents premium mot det volymvägda genomsnittet på de senaste riktade aktieemissionerna på cirka 1,1 SEK/aktie. Vid full konvertering av detta konvertibla skuldebrev skulle Norrlandsfonden erhålla 3 571 428 aktier i Copperstone, motsvarande 0,3 procents utspädning för befintliga aktieägare. “Vi är väldigt glada och stolta att Norrlandsfonden ännu en gång har beslutat att investera i Copperstone och